Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody positive adults with generalized myasthenia gravis. The Vivacity-MG3 study met its primary endpoint demonstrating statistically significant and clinically meaningful improvement over 24 weeks in the MG-ADLa score. Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation rates similar to placebo.